Business Valuation Expert Discusses Terms of Pharmaceutical Merger

Joseph O'Neill

Written by
— Updated on September 26, 2017

Valuation Expert WitnessThis case involves an individual who held a 15% stake in a publicly traded international business that conducted biomedical and pharmaceutical research. In the interest of acquiring a single, clinically important drug used in the treatment of autoimmune disorders, the individual proposed, negotiated, and established a merger agreement with another company that produced that drug exclusively. However, it was subsequently claimed that the terms of the merger agreement were not met, and that the valuation of the smaller company in the original merger agreement was significantly overestimated.

Question(s) For Expert Witness

  • 1. Please briefly describe your familiarity with the issues at hand in this case.
  • 2. Do you have experience valuing a single-asset, private pharmaceutical company with a license to develop a patent?

Expert Witness Response E-081422

I have been involved in 300+ M&A transactions over the course of my career. This includes experience at various stages, such as target identification, offers, acquisition, and integration. There is always a valuation/pricing component within the process. I do have experience advising on single-asset valuations, including some patent defense work while I worked at one of the big four professional services firms. While there, I dealt extensively with finance, M&A, and valuations involving pharmaceuticals, bio-pharmaceuticals, and medical devices. I served as an expert witness on several cases, including one in which I testified in court. I was tasked with looking at a company’s technology, performing a valuation, and coming up with a profit profile.

Contact this expert witness

Find a Business Expert Witness Near You

What State is your case in?

AL AK AZ AR CA CO CT DE DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY